Johnson & Johnson has secured European Commission approval for TECVAYLI, or teclistamab, in combination with daratumumab for adults with relapsed or refractory multiple myeloma who have received at least one previous therapy, moving the BCMA-directed bispecific antibody substantially earlier in the treatment pathway. The August 21, 2026 approval is based on the randomized Phase 3 MajesTEC-3 study, where the combination reduced the risk of disease progression or death by 83.4% compared with investigator-selected daratumumab-based standard regimens and also produced a statistically significant overall-survival advantage. The decision is consequently more important than a routine label expansion because it introduces an off-the-shelf BCMA-directed cellular-immune approach as early as second-line treatment, rather than reserving teclistamab largely for heavily pretreated patients.
MajesTEC-3 enrolled 587 patients who had received between one and three previous treatment lines, assigning 291 to teclistamab plus subcutaneous daratumumab and 296 to daratumumab and dexamethasone combined with either pomalidomide or bortezomib. At nearly three years of follow-up, the hazard ratio for progression or death was 0.17, while the hazard ratio for overall mortality was 0.46. Three-year overall survival reached 83.3% with the investigational combination compared with 65% in the control group, giving clinicians a survival result rather than relying solely on response depth or progression-free survival to justify moving a bispecific antibody earlier.
Why is moving teclistamab into second-line multiple myeloma such a significant change?
Teclistamab was originally introduced in Europe for a very different patient population: adults with relapsed or refractory multiple myeloma who had already received at least three prior therapies including an immunomodulatory medicine, a proteasome inhibitor and an anti-CD38 antibody. That late-line position reflected both the initial evidence available for the drug and concerns around the infection, cytopenia and cytokine-release risks associated with BCMA-targeted bispecific therapy. The new European indication takes teclistamab into patients whose disease has relapsed once, effectively asking physicians to use a potent immune-engaging therapy before several established drug classes have necessarily been exhausted.
The clinical rationale is that multiple myeloma typically becomes harder to control with each relapse. Remissions tend to become progressively shorter, while accumulated resistance and prior exposure narrow the number of treatments available later. Using a regimen capable of delivering deep and durable disease control sooner may therefore influence a patient’s disease trajectory more substantially than waiting until several additional treatment failures have occurred, although earlier use also means exposing patients to bispecific-antibody toxicities when they may still have other effective treatment options.
The MajesTEC-3 durability data strengthen that argument. Johnson & Johnson reported that more than 90% of patients who remained progression-free at six months were still progression-free at three years. While that statistic applies to a selected group that had already crossed the six-month landmark rather than the full randomized population, it suggests that some early responders achieve prolonged disease control rather than merely postponing progression for a few months.
How do teclistamab and daratumumab attack myeloma through different immune mechanisms?
Teclistamab is a bispecific antibody designed to bind B-cell maturation antigen on multiple myeloma cells while simultaneously engaging CD3 on T cells, physically bringing immune cells close to the malignant plasma cell and activating T-cell-mediated killing. Unlike autologous CAR-T therapy, which requires collection and individualized manufacturing of a patient’s cells, teclistamab is manufactured as an off-the-shelf pharmaceutical product and can therefore be initiated without a patient-specific production period.
Daratumumab targets CD38, a protein expressed at high levels on myeloma cells, and has become one of the foundational medicines in modern multiple myeloma treatment. Its effects are not limited to direct destruction of CD38-expressing tumor cells; daratumumab can also alter immunosuppressive cell populations and potentially create an environment in which T-cell-directed therapy becomes more active. Johnson & Johnson’s rationale is therefore that daratumumab improves immune fitness while teclistamab redirects activated T cells toward BCMA-positive myeloma cells, giving the two antibodies complementary rather than redundant functions.
That biological complementarity matters commercially because both agents are already established products. Johnson & Johnson is not attempting to introduce two experimental mechanisms simultaneously but to combine a mature CD38 franchise with a newer BCMA platform and move that combination progressively earlier through the disease course.
What safety trade-off accompanies the unusually large progression-free survival benefit?
The combination’s efficacy cannot be separated from the characteristic risks of immune-engaging myeloma treatment. In MajesTEC-3, cytopenias and infections were among the most frequent Grade 3 or Grade 4 treatment-emergent adverse events, while cytokine release syndrome occurred with teclistamab but all reported cases were Grade 1 or Grade 2 and none led to treatment discontinuation. Johnson & Johnson said treatment discontinuations caused by adverse events were relatively low and similar between the groups, at 4.6% for teclistamab and 5.5% for the comparator regimens.
Infections deserve particular attention because BCMA-directed therapy can impair normal plasma cells and antibody production in addition to destroying malignant cells. This means earlier adoption requires treatment centers to become comfortable not only administering the medicine but also implementing infection prophylaxis, monitoring immunoglobulins and managing recurrent or opportunistic infections over prolonged treatment.
The safety profile was described as consistent with the known profiles of the two agents, which is reassuring from a regulatory perspective but should not be interpreted as a low-toxicity regimen. The relevant clinical calculation is whether the magnitude and durability of the disease-control benefit justify those manageable but potentially serious risks in patients entering only their second treatment line.
Could MajesTEC-3 reset the competitive landscape around BCMA therapy?
BCMA has become one of the most competitive targets in multiple myeloma, with CAR-T therapies, bispecific antibodies and other approaches all competing for increasingly early positions. Historically, many BCMA therapies entered practice in very advanced disease because regulators and clinicians initially had evidence in patients who had exhausted conventional treatment. As randomized studies move these therapies earlier, the competitive question changes from whether BCMA targeting works to which platform provides the best combination of efficacy, durability, access, convenience and safety at each treatment stage.
Teclistamab’s off-the-shelf nature gives it an obvious accessibility advantage compared with individualized CAR-T manufacturing, although CAR-T can provide prolonged treatment-free intervals after a single infusion while teclistamab requires ongoing dosing. The European approval therefore does not end the debate over the optimal sequence of BCMA therapy; it makes that debate much more immediate because physicians can now consider a bispecific antibody after only one previous treatment.
European approval also builds on a broader regulatory expansion of the combination. The strength of MajesTEC-3 provides Johnson & Johnson with an unusually clear randomized survival dataset for positioning teclistamab earlier, and future treatment guidelines will determine whether that translates into routine second-line use or more selective adoption according to prior therapy and patient risk.
The central result is difficult to dismiss: an 83.4% relative reduction in progression or death and an overall-survival hazard ratio of 0.46 against established daratumumab-based regimens represent substantially more than incremental disease control. Europe has now translated those data into an earlier treatment indication, turning teclistamab from predominantly a late-line rescue therapy into a potential competitor for one of the most consequential positions in the multiple myeloma treatment sequence.
